FINWIRES · TerminalLIVE
FINWIRES

研究快訊:波克夏海瑟威第一季每股收益超出預期,但保險業務業績喜憂參半。

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:波克夏海瑟威2026年第一季營運每股收益為5.26美元,高於先前預期的4.47美元,也高於我們先前預測的5.10美元和市場普遍預期的5.05美元,營運收入成長4.4%。稅前營運利潤翻了一番多,利潤率從5.6%擴大至13%,但GEICO的承保業績惡化,綜合比率從79.8%上升至87.3%。我們認為,在經歷了2025年不到1%的收入成長後,營收溫和成長的恢復將令投資者感到安心,儘管保險業務表現喜憂參半。執行長格雷格·阿貝爾在其首次年度股東大會上重申了波克夏的收購策略和股票回購政策,但並未對預先設定的資本配置做出任何承諾。鑑於波克夏海瑟威擁有超過3,800億美元的現金,且2025年計畫零回購,預計其2026年第一季僅回購了2.35億美元的股票,因此我們估計該公司可能會將800億至1,000億美元用於收購。我們維持對該公司2026年3%至7%的營收成長預期,但考慮到其雄厚的現金儲備,我們預期投資者會期待該公司採取更積極的資本部署策略。

Related Articles

Research

Research Alert: Berkshire Q1 Eps Tops Expectations, With Mixed Insurance Results

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Berkshire's Q1 2026 operating EPS of $5.26 vs $4.47 topped our $5.10 estimate and $5.05 consensus view, with operating revenues rising 4.4%. Pretax operating profits more than doubled as margins widened to 13% from 5.6%, though GEICO's underwriting results deteriorated with combined ratio rising to 87.3% from 79.8%. We believe the resumption of modest top-line growth after 2025's sub-1% revenue growth will reassure investors, despite mixed insurance performance. CEO Greg Abel reiterated Berkshire's acquisition strategy and share buyback policy at his debut annual meeting, though provided no commitment to predetermined capital allocation. With cash exceeding $380B and only $235M in Q1 buybacks after zero repurchases in 2025, we estimate Berkshire could allocate $80-100B to acquisitions. We keep our 3%-7% revenue growth forecast for 2026, though expect investors hoped for more aggressive capital deployment given the substantial cash position.

$BRK.B
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Sofi Technologies, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $4 to $18, applying a P/E of 17.8x our 2028 EPS view vs. SOFI's 71.2x three-year historical forward P/E average. We keep our 2026 EPS estimate at $0.58, 2027's at $0.81, and 2028's at $1.01. We expect robust member and product growth, fueled by key initiatives like crypto and the SoFi Plus relaunch, to support sustained double-digit revenue expansion. The relaunched SoFi Plus introduces a paid subscription to fuel cross-selling, while the crypto initiative leverages its unique, bank-issued stablecoin to become a core infrastructure provider for digital assets.However, this outlook is reflected in a rich valuation that leaves minimal room for execution missteps. We remain neutral, as a sustained high-rate environment could stress consumers and impact credit performance, a key risk given the company's large personal loan portfolio. Management's decision to not raise full-year guidance, despite a strong quarter, balances strategic investments against macroeconomic uncertainties.

$SOFI
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Tenet Healthcare

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $200 from $260, 11.4x our 2026 EPS estimate (up to $17.56 from $17.33; 2027 estimate up to $18.00 from $17.85), a discount to the company's three-year historical forward average of 12.9x. We think THC's valuation balances recent deleveraging efforts and a stronger margin profile than in previous years against policy headwinds, including cuts to Medicaid coverage under the OBBBA legislation and the recent expiration of ACA enhanced premium tax credits, which increases risk of higher uncompensated care. Same-facility ACA exchange admissions fell 10% Y/Y in Q1, and THC guides for a 20% reduction in ACA exchange patient volumes for 2026 and anticipates a negative $250 million impact on adjusted EBITDA. While we expect THC to revisit annual guidance in Q2 earnings, at which point a clearer picture of the insurance coverage landscape is likely, we look favorably on the company maintaining its annual inpatient/outpatient volume guidance for now.

$THC